Hangzhou and Shaoxing, China, November 13, 2023 Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB ascletis.com/news_detail/18…

Hangzhou and Shaoxing, China, December 5, 2023 Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne ascletis.com/news_detail/18…

Shanghai, China, January 2nd, 2024 Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis ascletis.com/news_detail/18…

Shanghai, China, January 23, 2024 Gannex’s Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH ascletis.com/news_detail/18…

Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne ascletis.com/news_detail/18…

Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting ascletis.com/news_detail/18…

Hangzhou and Shaoxing, China, April 3, 2024 -- Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42. ascletis.com/news_detail/18…

Hangzhou, China, June 11, 2024--Gannex Announces Poster Presentation Describing Positive Interim 12-Week Results from Ongoing 52-Week Phase II Clinical Trial of Once-Daily ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024 ascletis.com/news_detail/18…

Hong Kong, China, Sep 17, 2024 – Ascletis Pharma Inc. (HKEX:1672)announces the completion of initial dosing in its two recently initiated U.S. Phase I clinical trials for ASC30. ascletis.com/news_detail/18…

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model ascletis.com/news_detail/18…

Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) announces today positive topline results from its U.S. single ascending dose (SAD) study (NCT06680440) of ASC30 oral tablet in patients with obesity (body mass index (BMI): 30-40 kg/m2). ascletis.com/news_detail/19…

Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 ascletis.com/news_detail/19…

Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide ascletis.com/news_detail/19…

Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist ascletis.com/news_detail/19…

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA ascletis.com/news_detail/19…

Ascletis announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity. ascletis.com/news_detail/19…

Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity ascletis.com/news_detail/19…

Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints ascletis.com/news_detail/19…

Ascletis Announces Poster Presentations on the Study Results of Oral Small Molecule GLP-1R Agonist ASC30 and Adipose-targeted, Muscle-preserving Weight Loss Drug Candidate ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA) ascletis.com/news_detail/19…

Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor for the Treatment of Psoriasis ascletis.com/news_detail/19…